Unbalanced translocations as well as interstitial deletions of the short arm of chromosome 12 [del(l2p)l are found as recurring drromosomal changes in a broad spectrum of hematopoietic malignancies. These changes result in the hemizygous deletion of genetic material from 12p. We mapped a yeast artificial chromosome containing the TEL gene, a cosmid contig containing part of E L and a P1 contig containing the KlPl gene to 12~13. These probes were used for fluorescence in situ hybridization to analyze samples from 47 patients with various hematologic malignancies who had unbalanced translocations (25 patients) leading to loss of 12p or deletions (22 patients) involving 12~13. The patients had acute lymphoblastic leukemia (8 cases), myelodysplastic ALANCED AND UNBALANCED translocations as well as interstitial deletions of the short arm of chromosome 12 are found as recurring abnormalities in both myeloid and lymphoid malignancies. Although several recurring 1 2~1 3 translocations have been identified [ie, t(5;12) (q33;p13),' t(7;12)(qll;p12-13),2 t(12;13)(~13;q14),~ t(12;17) (p13;q21)," t(l2;21)(~12;q22),~ and t(12;22)(p13;q12),6] a number of other chromosomal bands (6q 15, 7ql1, 7q36, 12q13, 12q22, and 22qll) have also been reported to be rearranged with 1 2~1 3 in various hematologic disorders. ' We showed that in the majority of balanced translocations, the breakpoint on 1 2~1 3 occurs within a yeast artificial chromosome (YAC 964~10) that also contains the TEL gene.' TEL forms a fusion transcript with the platelet-derived growth factor receptor+ gene on 5q33 in patients with chronic myelomonocytic leukemia and a t(5;12)(q33;p13).' TEL (translocation ets leukemia) has an ETS DNA-binding domain and as well as a predicted helix-loop-helix domain (HLH) and is a member of the ETS family of transcription factors. Recent studies by us have shown that TEL also forms fusion transcripts with a number of other genes, including ABL9." and AMLI." It is not known at present whether TEL is involved in all the of breakpoints that occur within YAC 964~10. The mechanism underlying the malignant transformation in the case of the TEL fusion proteins (TEL-PDGFRB, TEL-ABL, and TEL-AMLl) is not known.
Unbalanced translocations as well as interstitial deletions of the short arm of chromosome 12 [del(l2p)l are found as recurring drromosomal changes in a broad spectrum of hematopoietic malignancies. These changes result in the hemizygous deletion of genetic material from 12p. We mapped a yeast artificial chromosome containing the TEL gene, a cosmid contig containing part of E L and a P1 contig containing the KlPl gene to 12~13. These probes were used for fluorescence in situ hybridization to analyze samples from 47 patients with various hematologic malignancies who had unbalanced translocations (25 patients) leading to loss of 12p or deletions (22 patients) involving 12~13. The patients had acute lymphoblastic leukemia (8 cases), myelodysplastic ALANCED AND UNBALANCED translocations as well as interstitial deletions of the short arm of chromosome 12 are found as recurring abnormalities in both myeloid and lymphoid malignancies. Although several recurring 1 2~1 3 translocations have been identified [ie, t(5;12) (q33;p13),' t(7;12)(qll;p12-13),2 t(12;13)(~13;q14),~ t(12;17) (p13;q21)," t(l2;21)(~12;q22),~ and t(12;22)(p13;q12),6] a number of other chromosomal bands (6q 15, 7ql1, 7q36, 12q13, 12q22, and 22qll) have also been reported to be rearranged with 1 2~1 3 in various hematologic disorders. ' We showed that in the majority of balanced translocations, the breakpoint on 1 2~1 3 occurs within a yeast artificial chromosome (YAC 964~10) that also contains the TEL gene.' TEL forms a fusion transcript with the platelet-derived growth factor receptor+ gene on 5q33 in patients with chronic myelomonocytic leukemia and a t(5;12)(q33;p13).' TEL (translocation ets leukemia) has an ETS DNA-binding domain and as well as a predicted helix-loop-helix domain (HLH) and is a member of the ETS family of transcription factors. Recent studies by us have shown that TEL also forms fusion transcripts with a number of other genes, including ABL9." and AMLI." It is not known at present whether TEL is involved in all the of breakpoints that occur within YAC 964~10. The mechanism underlying the malignant transformation in the case of the TEL fusion proteins (TEL-PDGFRB, TEL-ABL, and TEL-AMLl) is not known.
Recurring loss of genetic material from specific chromosomal regions suggests the presence of a tumor-suppressor gene in these regions. Deletions affecting band 1 2~1 3 and unbalanced translocations with breakpoints in 1 2~1 3 , which both result in the loss of genetic material from the short arm of chromosome 12, are far more common than reciprocal translocations. In a recent review it was reported that the del( 12p) is one of the most common deletions in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), suggesting that the involved gene plays a critical role in growth regulation of all hematopoietic cells." Del( 12p) is found in about 5% of childhood ALL cases,' but also in patients with myelodysplastic syndrome (MDS) and AML, both de novo and therapy related, and in myeloproliferative disorders (MPD).' The true frequency of del( 12p) is probably higher because deletions may not be detectable by standard syndrome (MDS; 11 cases), acute myeloid leukemia (AML; 10 cases), myeloproliferative disorders (4 cases), therapyrelated MDS or AML (7 cases), non-Hodgkin's lymphoma (2 cases), and other hematopoietic malignancies (5 cases). All three probes were hemizygously deleted in 26 cases and were completely retained in only 9 cases. In 12 cases probes for one of the two genes were deleted, allowing us to map the smallest region of overlap of these deletions to a small genomic region that is bordered on the telomeric side by the E L gene and on the centromeric side by KlP1. The genomic distance between E L and KlPl is estimated to be about 1 to 2 Mbp. 0 1995 by The American Society of Hematology.
cytogenetic techniques. Loss of heterozygosity (LOH) on I2p was detected in 25% of ALL samples in a recent report.13 Kobayashi et a18 have recently shown that the telomeric border of a series of cytogenetically identified del( 12p) samples maps very close to the breakpoints of the reciprocal translocations. The centromeric limits of the deletions could not be very well defined in this fluorescence in situ hybridization (FISH) study. Most of the patients showed large deletions that included the most centromeric marker (D12S120) that mapped to 1 2~1 2 .
l. In this study, the smallest region of overlap (SRO) of the deletions spanned a relatively large genomic region flanked by D12S133 (12~13.1) distally and by D12S140 (12~12.1) proximally, which probably encompasses 5 to 10 Mbp (Fig l) .
In the present study, we were able to define the SRO of these deletions further by studying patients with del( 12p) or unbalanced translocations involving 12~13. The telomeric border of the smallest commonly deleted region is defined by the YAC 964clO that contains the TEL gene and the centromeric border of the deletions is defined by a P1 contig14 that contains the KIP1 gene.I5*l6 The protein encoded by KIP1, ~2 7~" ' .
is an inhibitor of the cyclin E-Cdk2 complex and is thought to play an important role in the arrest of contact-inhibited and transforming growth factor-o-inhibited cells in the G1 to S phase transition." Table 1 .
MATERIALS AND METHODS

Purients
Cytogenetic onulysis. Metaphase cells were prepared from bone marrow or peripheral blood as previously described." Thirty-two of the samples were obtained before treatment.
The karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN 1991).'" FISH probes. Three FISH probes were used for the deletion analysis, ie, YAC 964~10, a cosmid contig containing part of the TELgene, and a PI contig containing KIPI. The CEPH YAC 964cl0 has a human insert of 1,390 kb and contains the TEL gene as well as the sequence tagged sites (STSs) D12S89, D12S98, and D12S391.'" We obtained the cosmids from a cosmid library constructed from YAC 964~10 that was screened with a 1.4-kb TEL cDNA clone containing the entire coding sequence of TEL' The two cosmids in the contig cover approximately S0 kb and contain the middle portion of the TEL coding region. The PI contig consisted of two phages (addresses: 2096 and 2097; Genome Systems, Inc).
including the entire KIP I gene. In addition to these three probes, a cosmid, 1H9 (D12S142).R" was used for the two-color FISH mapping of KIPI. The YAC and the 1 H9 cosmid were kindly provided to us by Drs Kate Montgomery and Raju Kucherlapati (Albert Einstein College of Medicine, Bronx, NY). We also used centromere specific probes for chromosome 12 (CEP12 Spectrum Orange; Vysis, Framingham. MA), chromosome 13/21 and 14/22 (Chromosome 13/21 and Chromosome 14/22 Alpha Satellite DNA, digoxigenin-labeled; Oncor, Gaithersburg, MD), and whole chromosome painting probes for chromosome 7, 12, and X (Coatasome 7, Coatasome 12, and Coatasome X, digoxigenin-labeled; Oncor) to identify marker chromosomes or complicated rearrangements in some patients.
F K H . YAC964c10 was separated from the other yeast chromosomes with pulsed-field gel electrophoresis, the YAC band was excised, and the DNA was then sequence-independently amplified and labeled with biotin-l I-dUTP, as previously described.22 Ten nanograms of the PI phage DNA were amplified and labeled similarly. The cosmids were labeled with biotin-l I-dUTP or digoxigenin-lldUTP using nick translation. The telomere to centromere order of YAC964c10 and the PI contig was determined by two-color FISH analysis, as described previously.2' The probes were hybridized to For personal use only. on April 14, 2017. by guest www.bloodjournal.org From respectively. Abbreviations: AL, acute leukemia; AUL, acute undifferentiated leukemia; MF, myelofibrosis; NHL-LB(T), non-Hodgkin's lymphoma-lymphoblastic (T-cell origin); RA, refractow anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-T, RAEB in transformation; PV. polycythemia vera; DX, diagnosis; RL, relapse; AP, acute phase; BM, bone marrow sample; BC, bone core sample; PB, peripheral blood; PB-PHA, P9 phytohemagglutinin stimulated.
Patients with a del(12) and a der(l2) and no normal chromosome 12. The deletions and unbalanced translocations involving 1 2~1 3 are in boldface; reciprocal translocations involving 12p13 are underlined.
patient slides, as previously de~cribed.'~ Chromosomes were identified using counterstaining with 4' 6-diamidino-2-phenylindole dihydrochloride (DAPI). The presence or absence of the FISH signals was scored on an average of 12 abnormal metaphase cells (range, 2 to 20 cells) per probe per patient by two persons blinded to the identity of probes and patients.
Images of the hybridizations were captured with a liquid-cooled, charge-coupled device camera (Photometrics, Tucson, AZ). Separate gray-scale images for the DAPI and the fluorescein isothiocyanate (€WC) fluorescence were acquired. After adjusting the gray levels with the NM image 1.52 software (National Institutes of Health, Bethesda, MD), the images were merged in RGB format using Adobe Photoshop on a Macintosh computer (MacIntosh-Apple Corp, Cupertino, CA).
RESULTS
Ordering of probes. The P1 contig containing KIP1 was mapped to the region between TEL and D12S142 by twocolor FISH on normal metaphase chromosomes (tel-TEL-KIPI-Dl2S142-cen; Fig 1) . D12S142 was described previously as the closest marker centromeric to YAC Table 2 . FISH analysis was performed with YAC 9 6 4~1 0 and the KIPl contig. In those cases in which the YAC was retained, further analysis was performed using the TEL cosmids.
In patients no. 1 through 26, YAC964c10 and the KIPl P1 contig were hemizygously deleted (1 1 unbalanced translocations and 15 deletions). Signals for these probes were found only on the normal chromosome 12 but not on the der(l2) or del(12) chromosome. We called this a type 1 deletion (Figs 1 and 2A and B) .
In 4 patients (no. 27 through 30), the TEL cosmids and the KIPl contig were hemizygously deleted, whereas two signals were detected for YAC 964~10 (type 2 deletion; Figs 1 and 2C through E). In 3 cases (patients no. 27 through 29) with unbalanced translocations, the YAC signal was found not on the der( 12) chromosome but rather on other chromosomes, ie, on a marker chromosome, on chromosome 2, and on a der(14), respectively. Thus, these patients actually have translocations accompanied by deletions of DNA; the telomeric breakpoint of the deletiodtranslocation must be located within YAC 964~10.
In the 6 type 3 deletion cases (patients no. 31 through 36), only the KIP1 contig signal was hemizygously deleted, whereas both the YAC 9 6 4~1 0 and the TEL cosmid signals t The three probes were retained on the der(l2) in patients no. 26 and 32 and on Xqter in patient no. 33.
were retained (Figs 1 and 2F through H) . In 2 of these 6 cases (patients no. 31 and 34), additional FISH signals were detected with the YAC and TEL cosmid probe. Patient no. 3 1 had two clones, ie, a major clone with a der(l2) t(12;22)(p13;qll) and a minor clone with a t(5; 12) (q?15;p13). In the major clone, three YAC and TEL cosmid contig signals were detected in each metaphase: one on the normal chromosome 12, one on a marker chromosome, and one on a cytogenetically normal chromosome 21. In the minor clone with the t(5; 12)(q?15;p13), three YAC and TEL cosmid contig signals were detected: one on the normal chromosome 12, one on the der(5), and one on the der(l2). In patient no. 34, four YAC signals and two TEL cosmid contig signals were seen. The YAC signals were located on the normal 12, the der( 12), an add(9), and a marker chromosome. The two TEL cosmid contig signals were detected only on the normal 12 and the marker chromosome. In patients no. 31 and 34, the KIPl P1 signal was only present on the normal chromosome 12. These findings imply very complicated rearrangements in which multiple chromosomal breaks must have occurred in a small genomic region on 12p as well as on other chromosomes. The TEL gene is oriented 5' to 3', telomere to centromere, on 12p.I We cannot exclude that these type 3 deletions affect the 3' portion of TEL, because our cosmid contig does not contain the 3' portion of TEL (Fig 1) . Moreover, a small deletion of the TEL cosmid contig would not be detected in our FISH analyses.
In the 2 cases with type 4 deletions (patients no. 37 and 38), the YAC signal was hemizygously deleted, whereas the KIPl P1 contig signal was retained on both chromosome 12 homologues (Figs 1 and 21 and J) . We cannot exclude the possibility that these deletions affect KZPl because a FISH signal would still be visible if half or more of the DNA corresponding to the P1 contig was deleted. In patient no. 37, three KIPl P1 signals were observed: one on the normal chromosome 12, one on the der(l2), and one near the centromere of a der(2).
In 9 patients (no. 39 through 47) with rearrangements affecting 1 2~1 3 (8 unbalanced translocations and 1 deletion), none of the probes used in this study was deleted. Patient no. 39 probably has a balanced translocation, because the YAC 964~10 signal was found on a F-group chromosome, whereas the KIPl signal remained on the add(l2). In the remaining 8 patients, the three FISH probes were located on the same derivative chromosomes. These findings suggest that, in the patients with the unbalanced translocations (patients no. 40 through 44 and 46), the deletions affect the more distal portion of 12~13, whereas in patient no. 45, the deleted region is centromeric to KIPl as was shown by Kobayashi 
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Based on these data, the SRO for these deletions lies between TEL and KIPI. As noted earlier, we cannot exclude the possibility that the deletions include the 3' end of the TEL gene andor part of the KIPl gene as shown in Fig 1. However, it should be noted that we have observed deletions of 1 2~1 3 that apparently do not overlap this SRO.
No obvious correlation between the type of malignancy and the extent of the deletions was noted. Thirty-three patients had disorders affecting the myeloid lineage, including MDS (1 1 cases; t-MDS, 3 cases), AML (10 cases), therapyrelated AML (t-AML; 4 cases), chronic myeloid leukemia (CML; 1 case), or MPD (4 cases). Eleven patients had lymphoid disorders, including ALL (8 cases), chronic lymphocytic leukemia (CLL; 1 case), and non-Hodgkin's lymphoma (2 cases). Two patients had acute undifferentiated leukemia and 1 patient had an unspecified acute leukemia. Ten patients had simple karyotypes with one or two numerical or structural abnormalities (nos. 8, 11, 12, 13, 17, 22, 23, 24, 32, 40, and 47). Most cases had complex abnormal karyotypes with more than three numerical or structural abnormalities. In addition, these patients often had multiple clones that had related karyotypic changes. In the majority of these patients, the abnormal 12p was found in the simplest clone and was thus likely to be an early event. In 6 other patients, the 12p abnormality was a secondary event. Finally, 4 patients (no. 22, 31, 39, and 43), all of whom were studied only in relapse, had two or more independent clones with no common abnormalities. In 1 patient (no. 31), both clones involved 1 2~1 3 , and in 1 other patient (no. 43), the second clone was -12, +mar; therefore, involvement of 1 2~1 3 in both clones cannot be excluded. Of 5 patients whose sole karyotypic abnormality was a del(l2p) including the TEL-KIPI region, l had ALL, 1 had AML, and 3 had a myeloproliferative syndrome (2 with myelofibrosis and l with polycythemia vera).
DISCUSSION
In the present study we were able to define more precisely the SRO of hemizygous deletions on 1 2~1 3 .
By using patient samples that had unbalanced translocations as well as deletions it was possible to restrict the SRO to a small genomic segment bordered by TEL on the telomeric side and by KIPl on the centromeric side. The genomic distance between these two genes cannot be more than 2.9 Mbp because KIPl is contained within YAC 954810 that overlaps YAC 9641210 that contains TEL (S.K.B., unpublished observation; K.T.
Montgomery, personal communication, October 1994), and their combined size is about 2.9 Mbp. The actual distance between these genes is probably much shorter. Unfortunately, the FISH probes we used did not allow us to exclude either one of these two genes from the deleted region. In the type 3 deletions (Fig 1) in which we found loss of the KIPI P1 phage only, part of YAC964c10 andor the TEL cosmid contig and thus the 3' end of TEL could have been deleted. The TEL cosmid contig spans only about 50 kb of genomic sequence that corresponds to the middle portion of the coding sequence of TEL. Similarly, in the type 4 deletions in which only the KIP1 P1 phage is retained and both the YAC and the TEL cosmid contig are deleted, part of the KIPl P1 phage could be deleted, possibly including KIPl itself. Clearly, further studies with probes that map between TEL and KIPI are needed to determine the true extent of the hemizygous deletions in the 8 cases with type 3 and type 4 deletions. Interestingly, we have not found any evidence for homozygous deletions of 1 2~1 3 by FISH. This is quite different from the situation involving band 9p21 in which the two putative tumor-suppressor genes CDKN2 and the gene for ~1 5 '~~~~ together with large genomic regions are frequently homozygously deleted.25-28 It should also be noted that we observed deletions of 1 2~1 3 that affect regions both distal and proximal to the TEL-KIP1 interval.
Although the involvement of TEL in fusion genes indicates that it may act in a dominant fashion, both TEL and KIPl are candidate tumor-suppressor genes because they may map to the SRO that we have defined on 12p. Tumorsuppressor genes function as negative regulators of cell growth. According to Knudson's classical two-hit model, both alleles of a tumor-suppressor gene must be inactivated to initiate a tumor or to allow a tumor to progres~.~'
The KIPl gene product, ~2 7~" ' , is an inhibitor of the cyclin E-Cdk2 c0rnp1ex.l~"' ~2 7~' " is involved in mediating the signals from contact inhibition and transforming growth factor+ that result in cell cycle arrest in late G1 phase.17 It has also been shown that interleukin-2 treatment inactivates ~2 7~" ' in T lymphocytes, which can then progress from G1 to S phase." These findings suggest that ~2 7~" ' is likely to play an important negative role in the growth-regulatory pathways of at least some hematopoietic cell lineages. These observations make KIPl an excellent candidate tumor-suppressor gene.
One copy of KIPl was deleted in 75% of our tumor samples. To examine the possibility that the remaining allele is inactivated by a point mutation, the coding region and exonintron boundaries of the remaining allele were sequenced in 8 of our patients (no. 3, 15, 16, 18, 20, 26, 30 , and 32).14 No inactivating mutations of KIPI were found in these 8 TEL probably acts either alone or in concert with other proteins as a transcription factor. The target genes that are regulated by TEL and whether TEL suppresses or activates those genes are unknown. Interestingly, the amino acid sequence of the 5' HLH domain and the 3' DNA-binding domain of TEL is more closely related to the product of the Drosophila gene yadpok than to the corresponding domains of any human ETS family member.34,3s Whereas most ETS family members that have been studied in detail act as activators of transcription," it has recently been shown in cultured insect cells that the yadpok gene product represses the transcriptional activity of pointed, another member of the ETS family.36 Thus, the TEL gene could normally function as a negative regulator of transcription, which would make TEL a candidate tumor-suppressor gene. Whether the remaining TEL allele in the hemizygous deletions has mutations is unknown. However, in several leukemic patient samples with reciprocal translocations involving TEL, the remaining TEL allele is deleted. Thus, no normal TEL protein could have been present in the leukemia cells, because one allele was deleted and the other allele gave rise to a fusion protein (eg, TEL-ABL'" and TEL-AMLI ' I ) . In these cases it is difficult to distinguish between the effects resulting from the complete absence of a normal TEL gene product and the effects of the fusion protein. To confirm the role of TEL as a tumor-suppressor gene in our series of hemizygous deletions, we will examine the remaining TEL allele for mutations.
A further explanation for the deletion patterns observed is that there is more than one target. One target could be TEL or a gene telomeric to TEL; the other could be KlPl or a gene centromeric to KlPZ. Finally, there is the possibility that an as yet unidentified gene lies in the interval between TEL and KIPl and that it is the important tumor-suppressor gene in that region. Further studies with FISH probes that lie between TEL and KIPl are underway to resolve this uncertainty.
